OR WAIT null SECS
© 2023 MJH Life Sciences and Consultant Live. All rights reserved.
November 13, 2023
David Lally, MD highlights safety signals observed with GA therapies in clinical trials and the future of the treatment landscape.
David Lally, MD describes individual phenotypic features in geographic atrophy and determining patient response to treatment.
David Lally, MD describes the association of the complement system with geographic atrophy and how the 2 FDA-approved therapies for GA work to block the complement system.
David Lally, MD, discusses biomarkers for the progression of geographic atrophy and the lack of previous treatment options for the disease.